Palatin Obtains Imaging Agent Approval, Aims For General Infection Nod
This article was originally published in The Gray Sheet
Executive Summary
Palatin/Mallinckrodt's NeutroSpec imaging agent will be available in mid-August, following FDA approval July 2 for diagnosing equivocal appendicitis in patients aged five years and older with atypical symptoms
You may also be interested in...
Palatin's LeuTech Clinically Useful For Appendicitis Diagnosis - FDA Panel
Clinical management decisions on whether to use computed tomography (CT) or Palatin's LeuTech imaging agent for detecting appendicitis in patients with equivocal appendicitis likely will depend on an institution's level of expertise with each modality.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.